Promotional investment grows Diovan and Zelnorm brands, Novartis marketing chief says

Share this article:
An investment in promotional strategy has helped fuel new prescription growth for Novartis brands Diovan and Zelnorm, chief marketing officer Kurt Graves said yesterday during UBS’ Global Life Sciences conference in New York. Graves highlighted Diovan’s “BP Success Zone” campaign, along with DTC advertising for Zelnorm, as marketing efforts that have helped Novartis boost its bottom line in recent months. “BP Success Zone has helped complement Diovan…growing sales 38.2% in June…And as a result of DTC investment, prescriptions for Zelnorm have been growing by over 30%,” Graves said. Novartis works with MicroMass Communications on its BP Success Zone efforts and Deutsche for its Zelnorm DTC ads. Meanwhile, Novartis remains optimistic about launches for a slew of pipeline products in the months ahead, with a sharp focus on Galvus (type 2 diabetes) and Exforge (hypertension). Detailing efforts for the new drugs will be category dependent, pending approval, Graves said. “What we don’t want to tell you is how we have set up our field force,” he added. “Every pharma company needs to come up with innovative go-to market strategies,” if it wants to be successful. Nancy Lurker, Novartis’ recently appointed SVP, chief marketing officer, said during a conference breakout session, that the scope of Novartis’ marketing efforts will undergo some changes in light of these anticipated new product launches. “You don’t see it growing; however, the channels are broadening,” she said.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.